It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Porphyromonas gingivalis is a member of the dysbiotic oral microbiome and a “keystone pathogen” that causes severe periodontal disease, which is among the most prevalent infectious diseases. Part of the virulence factors secreted by P. gingivalis are the essential cysteine peptidases gingipain K (Kgp) and R (RgpA and RgpB), which account for 85% of the extracellular proteolytic activity of the pathogen and are thus prime targets for inhibition. We report the high-resolution (1.20 Å) complex structure of Kgp with KYT-36, a peptide-derived, potent, bioavailable and highly selective inhibitor, which is widely used for studies in vitro, in cells and in vivo. Sub-nanomolar inhibition of Kgp is achieved by tight binding to the active-site cleft, which is covered for its sub-sites S3 through S1’ under establishment of nine hydrophobic interactions, 14 hydrogen bonds and one salt bridge. In addition, an inhibitor carbonyl carbon that mimics the scissile carbonyl of substrates is pyramidalized and just 2.02 Å away from the catalytic nucleophile of Kgp, C477Sγ. Thus, the crystal structure emulates a reaction intermediate of the first nucleophilic attack during catalysis of cysteine peptidases. The present study sets the pace for the development of tailored next-generation drugs to tackle P. gingivalis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Ksiazek Miroslaw 3 ; Potempa, Barbara A 4 ; Potempa, Jan 3 ; Xavier, Gomis-Rüth F 1
1 Molecular Biology Institute of Barcelona (CSIC), Barcelona Science Park, Proteolysis Lab, Structural Biology Unit, “María de Maeztu” Unit of Excellence, Barcelona, Spain (GRID:grid.428973.3) (ISNI:0000 0004 1757 9848)
2 University of Warsaw, Department of Bacterial Genetics, Faculty of Biology, Warszawa, Poland (GRID:grid.12847.38) (ISNI:0000 0004 1937 1290); University of Louisville School of Dentistry, Department of Oral Immunology and Infectious Diseases, Louisville, USA (GRID:grid.266623.5) (ISNI:0000 0001 2113 1622)
3 University of Louisville School of Dentistry, Department of Oral Immunology and Infectious Diseases, Louisville, USA (GRID:grid.266623.5) (ISNI:0000 0001 2113 1622); Jagiellonian University, Department of Microbiology, Faculty of Biochemistry, Biophysics and Biotechnology, Kraków, Poland (GRID:grid.5522.0) (ISNI:0000 0001 2162 9631)
4 Jagiellonian University, Department of Microbiology, Faculty of Biochemistry, Biophysics and Biotechnology, Kraków, Poland (GRID:grid.5522.0) (ISNI:0000 0001 2162 9631)




